Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of
tolerance than rifampicin regarding the risk of interaction with concomitant medications and
liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as
efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety
profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared
with rifampicin prescribed in combination treatment for PJIs.